2-{1-[1-Carboxy-2-(3'-methoxy-biphenyl-4-yl)-ethylcarbamoyl]-10-oxo-heptadec-2-enyl}-2-hydroxy-succinic acid | 827035-62-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-{1-[1-Carboxy-2-(3'-methoxy-biphenyl-4-yl)-ethylcarbamoyl]-10-oxo-heptadec-2-enyl}-2-hydroxy-succinic acid
• 英文别名: (2S)-2-[(E,2S)-1-[[(1S)-1-carboxy-2-[4-(3-methoxyphenyl)phenyl]ethyl]amino]-1,11-dioxooctadec-3-en-2-yl]-2-hydroxybutanedioic acid
• CAS: 827035-62-1
• 化学式: C₃₈H₅₁NO₁₀
• 分子量: 681.824
• InChiKey: GHXROQIKFKIPRW-ORHZTSPUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.5
• 重原子数：
  49
• 可旋转键数：
  25
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  188
• 氢给体数：
  5
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  (2R,3S)-5-[tert-butyl(diphenyl)silyl]oxy-3-[[tert-butyl(diphenyl)silyl]oxymethyl]-2-[(E)-8-(2-heptyl-1,3-dioxolan-2-yl)oct-1-enyl]pentane-1,3-diol 在 sodium chlorite 、 sodium dihydrogenphosphate 、 Jones reagent 、 草酰氯 、 四丁基氟化铵 、 4-甲基苯磺酸吡啶 、 溶剂黄146 、 二甲基亚砜 、 三乙胺 、 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 、 三氟乙酸 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 、 丙酮 、 叔丁醇 为溶剂， 生成 2-{1-[1-Carboxy-2-(3'-methoxy-biphenyl-4-yl)-ethylcarbamoyl]-10-oxo-heptadec-2-enyl}-2-hydroxy-succinic acid
  参考文献：
  名称：

  NA255作为新型靶向宿主的抗HCV药物的开发中，衍生物的对映选择性合成及其构效关系研究

  摘要：

  丙型肝炎病毒（HCV）感染代表严重的医疗保健问题。以前，我们报道了使用HCV亚基因组复制子细胞培养系统从天然产物库中鉴定出NA255。在这里，我们报告如何确定NA255的绝对立体化学，并开发了NA255衍生物的对映选择性合成方法。公开了NA255衍生物的结构活性关系和代表性化合物的大鼠药代动力学特征。

  DOI：

  10.1016/j.bmcl.2012.10.083

文献信息

• Method Of Producing Compound Having Anti-Hcv Activity
  申请人：Aoki Masahiro

  公开号：US20110098477A1

  公开（公告）日：2011-04-28

  There is provided a convenient and inexpensive method of producing a compound which has a high activity of inhibiting replication of hepatitis C virus (HCV) and is useful for preventing and treating a liver disease caused by HCV infection. It is a method of biologically producing a compound represented by the formula (1): [wherein A represents a hydrogen atom, a straight or branched alkyl group having 1 to 8 carbon atoms, or the like], or a pharmaceutically acceptable salt thereof, a method comprising adding an amino acid derivative represented by the formula (3): [wherein A has the same meaning as defined for the compound of the above formula (1); and R represents a hydrogen atom, a straight or branched alkyl group having 1 to 8 carbon atoms, or the like], or a salt thereof into the fungal mycelium or the culture medium/culture broth of a filamentous fungal strain having an ability to produce the compound represented by the formula (2): to thereby cause the fungal strain to directly produce the compound of the formula (1).

  提供了一种方便且廉价的方法，用于生产一种具有高抑制丙型肝炎病毒（HCV）复制活性的化合物，并且可用于预防和治疗由HCV感染引起的肝病。这是一种生物学生产一种由以下化学式（1）表示的化合物的方法：[其中A代表氢原子、具有1至8个碳原子的直链或支链烷基基团，或类似物]，或其药学上可接受的盐的方法，包括将由以下化学式（3）表示的氨基酸衍生物添加到具有生产由以下化学式（2）表示的化合物的能力的丝状真菌菌株的真菌菌丝或培养基/培养液中，从而使真菌菌株直接产生化合物的化学式（1）。
• EP1857456
  申请人：——

  公开号：——

  公开（公告）日：——
• Production Process of Compound Having Anti-Hcv Action and Intermediate Thereof
  申请人：Kato Tatsuya

  公开号：US20080293950A1

  公开（公告）日：2008-11-27

  A method whereby a compound having HCV replication inhibitory activity and desired optical activity can be synthesized selectively and at high yield in a small number of steps by using a compound having a specific chiral auxiliary as a starting compound is provided. A compound represented by the formula (1-8): [wherein Y represents a group represented by the following formula: Q represents a protected carbonyl group; D represents —(CH 2 ) m —R′, etc.; and n represents an integer of 0 to 10].
• Intermediate compound for synthesis of viridiofungin a derivative
  申请人：Kato Tatsuya

  公开号：US20100152456A1

  公开（公告）日：2010-06-17

  A method whereby a compound having HCV replication inhibitory activity and desired optical activity can be synthesized selectively and at high yield in a small number of steps by using a compound having a specific chiral auxiliary as a starting compound is provided. A compound represented by the formula (1-8): wherein Y represents a group represented by the following formula: Q represents a protected carbonyl group; D represents —(CH 2 ) m —R′, etc.; and n represents an integer of 0 to 10.
• PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OR PREVENTION OF HBV INFECTION
  申请人：Mizokami Masashi

  公开号：US20110160252A1

  公开（公告）日：2011-06-30

  First, the present inventors assessed the effect of the compound represented by formula (III) below on Huh-7 cells infected with HBV, and demonstrated that the compound alone had an anti-HBV effect in vitro. Formula (III) Then, the present inventors revealed that the HBV replication-suppressing effect of PEG-IFN is enhanced in chimeric mice having a human liver infected with genotype C or A HBV when PEG-IFN is used in combination with the compound represented by formula (III) above. The present inventors also revealed that the HBV replication-suppressing effect of Entecavir is enhanced in chimeric mice having a human liver infected with genotype C HBV (wild-type and Entecavir-resistant strains) when Entecavir is used in combination with the compound represented by formula (III) above. In addition, the present inventors revealed that the compound represented by formula (III) above exerts the anti-HBV effect not only against wild-type HBV strains but also against Entecavir- and/or Lamivudine-resistant HBV strains.